The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis

被引:3
|
作者
Frascoli, Federico [1 ]
Roos, Izanne [2 ,3 ]
Malpas, Charles B. [2 ,3 ]
Kalincik, Tomas [2 ,3 ]
机构
[1] Swinburne Univ Technol, Dept Math, Fac Sci Comp & Engn Technol, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, CORe, Melbourne, Vic 3050, Australia
[3] Royal Melbourne Hosp, Melbourne MS Ctr, Dept Neurol, Melbourne, Vic 3050, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Population models; Multiple sclerosis; Drug trials; MATHEMATICAL-MODEL; ASSOCIATION; THERAPY; MRI;
D O I
10.1016/j.jtbi.2022.111091
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for the response to disease modifying therapies is proposed. With a population approach and separate states for patients accounting for their risk of relapses, a system of nonlinear equations is formulated, similarly to established epidemiological models. Different parameters describe the effect of drugs and treatment switch in reducing the frequency of relapses. The model allows for a good fit to previously published data for experiments where different drugs are used. It also shows that different treatments maintain a high degree of similarity, with analogous dynamical features: a pre-treatment increment in relapse frequency leading to a distinct peak, a rapid drop after treatment switch and a plateau corresponding to a new base relapse activity, which seems dependant on the treatment chosen. A sensitivity analysis shows that the uncertainty in the initial proportions of different populations and the frequency of relapses can modify the overall dynamics of the response to treatment. Drugs are observed to induce effects that depend on patient sample's intrinsic characteristics, producing two clearly distinct and independent dynamics of relapse response. This confirms the clinical observation that certain drugs may be overall more successful in lowering the rate of relapses more significantly than others, notwithstanding the fact that patients behave differently across experiments. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] BUDGETARY IMPACT OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Garcia-Ruiz, A. J.
    Izquierdo Ayuso, G.
    Garcia-Agua Soler, N.
    VALUE IN HEALTH, 2012, 15 (07) : A548 - A548
  • [42] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
    Bomprezzi, Roberto
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
  • [43] Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis
    Sharim, Justin
    Tashjian, Randy
    Golzy, Nima
    Pouratian, Nader
    JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 30 : 166 - 168
  • [44] Interferon β treatment in relapsing-remitting multiple sclerosis.: A review
    Grigoriadis, N
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 251 - 258
  • [45] Comparison of immunomodulatory therapies in treatment of relapsing-remitting multiple sclerosis
    Aydin Canturk, I.
    Isik, N.
    Unsal, A.
    Arici, O.
    Yildiz, N.
    Candan, F.
    MULTIPLE SCLEROSIS, 2006, 12 : S96 - S96
  • [46] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [47] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: the Chieti experience
    di Ioia, M.
    Travaglini, D.
    Di Tommaso, V.
    Mancinelli, L.
    Pietrolongo, E.
    De Luca, G.
    Farina, D.
    Lugaresi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 754 - 754
  • [48] Oral therapies for treatment of relapsing-remitting multiple sclerosis in austria
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 179 - 179
  • [49] Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
    de Flon, Pierre
    Gunnarsson, Martin
    Laurell, Katarina
    Soderstrom, Lars
    Birgander, Richard
    Lindqvist, Thomas
    Krauss, Wolfgang
    Dring, Ann
    Bergman, Joakim
    Sundstrom, Peter
    Svenningsson, Anders
    NEUROLOGY, 2016, 87 (02) : 141 - 147
  • [50] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196